Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral semaglutide in type 2 diabetes inadequately controlled with diet and exercise
CTR20191200Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Sep 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20191200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191200.